Metronidazole Benzoate belongs to the antibiotic class and achieves its selective antibacterial effect by inhibiting a bacterial enzyme or structural component essential for pathogen survival and replication while maintaining a defined safety margin against mammalian cell toxicity. The selectivity index between the antibacterially effective concentration and the mammalian cytotoxic concentration defines the therapeutic window. PDE derivation for Metronidazole Benzoate draws on the critical repeat-dose toxicity study in rodents or higher species, with the NOAEL serving as the point of departure before application of composite uncertainty factors.
The severe toxicity modifier F4 in PDE derivation for Metronidazole Benzoate is applied when the nature of the critical adverse effect warrants additional conservatism beyond the default interspecies and intraspecies uncertainty factors.
